These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12577860)

  • 21. [Pharmacological treatment of obesity and syndrome X].
    Thissen JP
    J Pharm Belg; 2001; 56(2):45-50. PubMed ID: 11396351
    [No Abstract]   [Full Text] [Related]  

  • 22. Obesity: the fat lady sings?
    Cairns E
    Drug Discov Today; 2005 Mar; 10(5):305-7. PubMed ID: 15749277
    [No Abstract]   [Full Text] [Related]  

  • 23. [Pharmacotherapy of obesity].
    Svendsen OL
    Ugeskr Laeger; 2004 Oct; 166(43):3814-7. PubMed ID: 15544112
    [No Abstract]   [Full Text] [Related]  

  • 24. Another type of intervention: treating obesity with medication.
    Greenway F
    J Am Diet Assoc; 2005 Jun; 105(6):895-8. PubMed ID: 15942538
    [No Abstract]   [Full Text] [Related]  

  • 25. Obesity pharmacotherapy from a regulatory perspective: overview and key challenges.
    Hutchinson NI; Ryder SW
    Clin Pharmacol Ther; 2007 May; 81(5):756-60. PubMed ID: 17392723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term pharmacotherapy for obesity.
    Klein S
    Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacotherapy of childhood obesity: an evidence-based, conceptual approach.
    Freemark M
    Diabetes Care; 2007 Feb; 30(2):395-402. PubMed ID: 17259519
    [No Abstract]   [Full Text] [Related]  

  • 28. Cetilistat, a new lipase inhibitor for the treatment of obesity.
    Padwal R
    Curr Opin Investig Drugs; 2008 Apr; 9(4):414-21. PubMed ID: 18393108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diet-pill dilemma. When willpower fails, are antiobesity drugs worth the risk of less-than-pleasant side effects?
    Gupta S
    Time; 2007 Dec; 170(24):76. PubMed ID: 18159801
    [No Abstract]   [Full Text] [Related]  

  • 30. Obesity market overview.
    Farrigan C; Pang K
    Nat Rev Drug Discov; 2002 Apr; 1(4):257-8. PubMed ID: 12120276
    [No Abstract]   [Full Text] [Related]  

  • 31. [Xenical--a modern perspective drug for the treatment of obesity (review)].
    Mkrtumian AM; Biriukova EV
    Ter Arkh; 2007; 79(10):35-9. PubMed ID: 18154143
    [No Abstract]   [Full Text] [Related]  

  • 32. Development of novel medications for use in the treatment of obesity in children will be directed by delineating controls of energy homeostasis.
    Sherman PM; Zlotkin SH
    Arch Pediatr Adolesc Med; 2003 Aug; 157(8):721. PubMed ID: 12912773
    [No Abstract]   [Full Text] [Related]  

  • 33. Obesity: new perspectives and pharmacotherapies.
    Palamara KL; Mogul HR; Peterson SJ; Frishman WH
    Cardiol Rev; 2006; 14(5):238-58. PubMed ID: 16924165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DGAT inhibitors for obesity.
    Matsuda D; Tomoda H
    Curr Opin Investig Drugs; 2007 Oct; 8(10):836-41. PubMed ID: 17907060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents.
    Nilsson BM
    J Med Chem; 2006 Jul; 49(14):4023-34. PubMed ID: 16821762
    [No Abstract]   [Full Text] [Related]  

  • 36. Growth hormone secretagogue receptor antagonists as anti-obesity therapies? Still an open question.
    Zhao H; Liu G
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):509-15. PubMed ID: 16889233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Believes diet drug use ignores cause of pet obesity.
    Stuart B
    J Am Vet Med Assoc; 2007 Apr; 230(8):1144. PubMed ID: 17514838
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacological and surgical treatments for obesity.
    DeWald T; Khaodhiar L; Donahue MP; Blackburn G
    Am Heart J; 2006 Mar; 151(3):604-24. PubMed ID: 16504622
    [No Abstract]   [Full Text] [Related]  

  • 39. The success of bariatric surgery as treatment of type 2 diabetes should be a call to revitalize anti-obesity drug discovery and development.
    Opgenorth TJ
    Curr Opin Investig Drugs; 2008 Apr; 9(4):355-6. PubMed ID: 18393101
    [No Abstract]   [Full Text] [Related]  

  • 40. Fat oxidation in obesity: druggable or risky enterprise?
    Clapham JC
    IDrugs; 2004 Mar; 7(3):238-42. PubMed ID: 15011098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.